Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model
Not only CAR-T cells but also CB-derived CAR-NK cells targeting B7-H3 may have the potential to eliminate GBM cells.
Authors
- Tetsuro Tachi
- Reina Utsugi
- Koki Murakami
- Haruhiko Kishima (ORCID: https://orcid.org/0000-0002-9041-2337)
- Ryuichi Hirayama (ORCID: https://orcid.org/0000-0002-3739-6219)
- Naoki Hosen (ORCID: https://orcid.org/0000-0001-9570-0947)
- Noriyuki Kijima (ORCID: https://orcid.org/0000-0003-2103-1909)
- Yoshiko Okita (ORCID: https://orcid.org/0000-0002-2943-238X)
- Chihaya Imai (ORCID: https://orcid.org/0000-0001-7435-3464)
- Moto Yaga (ORCID: https://orcid.org/0000-0001-6649-6887)
- Hideki Kuroda
- Syunya Ikeda
- Kanji Nakagawa
- N. Kagawa
- Tomoyoshi Nakagawa
Institutions
- Osaka City General Hospital (JP)
- University of Toyama (JP)
- Osaka International University (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2024-10-05
- DOI
- https://doi.org/10.1007/s00262-024-03808-0
- Citations
- 18
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 5.09
Funders
- Takeda Science Foundation
- Japan Agency for Medical Research and Development
- Fondation pour la Recherche Médicale
- Osaka University
- Astellas Pharma
- Mochida Memorial Foundation for Medical and Pharmaceutical Research
- Japan Brain Foundation
- Japan Society for the Promotion of Science